Literature DB >> 30141010

Defining High Endothelial Venules and Tertiary Lymphoid Structures in Cancer.

Emma Jones1, Awen Gallimore2, Ann Ager2.   

Abstract

High endothelial venules (HEVs) are structurally distinct blood vessels that develop during embryonic and neonatal life in all secondary lymphoid organs except the spleen. HEVs are critical for initiating and maintaining immune responses because they extract naïve and memory lymphocytes from the bloodstream, regardless of antigen receptor specificity, and deliver them to antigen-presenting cells inside lymph nodes under homeostatic conditions. HEVs also develop postnatally in nonlymphoid organs during chronic inflammation driven by autoimmunity, infection, allografts, and cancer. Extranodal HEVs are usually surrounded by dense lymphocytic infiltrates organized into lymph-node like, T- and B-cell-rich areas called tertiary lymphoid structures (TLS). HEV neogenesis is thought to facilitate the generation of tissue-destroying lymphocytes inside chronically inflamed tissues and cancers.We are studying the mechanisms underpinning HEV neogenesis in solid cancers and the role of homeostatic T-cell trafficking in controlling cancer immunity. In this chapter we describe methods for identifying HEV in tissue sections of cancerous tissues in humans and mice using immunohistochemical staining for the HEV-specific marker peripheral lymph node addressin (PNAd). L-selectin binding to PNAd is a necessary first step in homeostatic lymphocyte trafficking which is the defining function of HEV. We also describe methods to measure L-selectin-dependent homing of lymphocytes from the bloodstream into lymphoid tissues and tumors in preclinical cancer models.

Entities:  

Keywords:  High endothelial venule (HEV); L-selectin (CD62L); Lymphocyte homing; Mucosal addressin cell adhesion molecule-1 (MAdCAM-1); Naïve T lymphocyte; Peripheral lymph node addressin (PNAd); Tertiary lymphoid structure (TLS)

Mesh:

Substances:

Year:  2018        PMID: 30141010     DOI: 10.1007/978-1-4939-8709-2_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

Review 1.  Current concept for tertiary lymphoid structures in urothelial carcinoma of the bladder: a literature review and our experience.

Authors:  Milena Gulinac; Dorian Dikov; Simeon Lichev; Tsvetelina Velikova
Journal:  Am J Clin Exp Immunol       Date:  2020-12-15

2.  Lymphatic drainage from bronchus-associated lymphoid tissue in tolerant lung allografts promotes peripheral tolerance.

Authors:  Wenjun Li; Jason M Gauthier; Alice Y Tong; Yuriko Terada; Ryuji Higashikubo; Christian C Frye; Margaret S Harrison; Kohei Hashimoto; Amit I Bery; Jon H Ritter; Ruben G Nava; Varun Puri; Brian W Wong; Kory J Lavine; Ankit Bharat; Alexander S Krupnick; Andrew E Gelman; Daniel Kreisel
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 3.  Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies.

Authors:  Hua Zhao; Hao Wang; Qiuru Zhou; Xiubao Ren
Journal:  Cancer Biol Med       Date:  2021-09-24       Impact factor: 5.347

4.  High Endothelial Venules and Pancreatic Ductal Adenocarcinoma: A potential game changer.

Authors:  Shu Ming Chai; Ser Yee Lee
Journal:  EBioMedicine       Date:  2018-12-05       Impact factor: 8.143

Review 5.  Immune function and dysfunction are determined by lymphoid tissue efficacy.

Authors:  Spyridon Makris; Charlotte M de Winde; Harry L Horsnell; Jesús A Cantoral-Rebordinos; Rachel E Finlay; Sophie E Acton
Journal:  Dis Model Mech       Date:  2022-01-24       Impact factor: 5.758

6.  Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer.

Authors:  Meng Qin; Junzo Hamanishi; Masayo Ukita; Koji Yamanoi; Shiro Takamatsu; Kaoru Abiko; Ryusuke Murakami; Taito Miyamoto; Haruka Suzuki; Akihiko Ueda; Yuko Hosoe; Akihito Horie; Ken Yamaguchi; Masaki Mandai
Journal:  Cancer Immunol Immunother       Date:  2021-10-23       Impact factor: 6.630

Review 7.  Tertiary Lymphoid Structures as Mediators of Immunotherapy Response.

Authors:  Raj G Vaghjiani; Joseph J Skitzki
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

8.  Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.

Authors:  Sarah Nicol Lauder; Kathryn Smart; Veerle Kersemans; Danny Allen; Jake Scott; Ana Pires; Stefan Milutinovic; Michelle Somerville; Sean Smart; Paul Kinchesh; Elena Lopez-Guadamillas; Ellyn Hughes; Emma Jones; Martin Scurr; Andrew Godkin; Lori S Friedman; Bart Vanhaesebroeck; Awen Gallimore
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

Review 9.  STING Agonists as Cancer Therapeutics.

Authors:  Afsaneh Amouzegar; Manoj Chelvanambi; Jessica N Filderman; Walter J Storkus; Jason J Luke
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

Review 10.  STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.

Authors:  Jessica N Filderman; Mark Appleman; Manoj Chelvanambi; Jennifer L Taylor; Walter J Storkus
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.